What is the process for staging sarcoma and determining treatment options?

Staging of Sarcoma

Initial Diagnostic Approach

All suspected sarcomas must be managed at a specialized sarcoma reference center with multidisciplinary team (MDT) involvement from the outset, and biopsy should be performed under the supervision of the treating surgical team or dedicated interventional radiologist. 1

Biopsy Technique

• Core needle biopsy (multiple cores, not fine-needle aspiration) is the preferred diagnostic method, performed under imaging guidance (ultrasound, CT, or X-ray) 1
• The biopsy tract must be planned so it can be excised during definitive surgery, as it is considered contaminated with tumor 1
• Use longitudinal incisions if open biopsy is required; mark the tract with ink tattoo for future identification 1
• Excisional biopsy is contraindicated for aggressive-benign or malignant lesions, as it contaminates additional tissue compartments 1
• All pathology must be reviewed by a specialist sarcoma pathologist, as discrepancy rates range from 8-35% when diagnosed outside specialist centers 1

Pathological Assessment

Essential Pathology Elements

• Histological grading using the FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer) system is mandatory, which scores differentiation, necrosis, and mitotic count to determine grades 1-3 1
• Molecular pathology testing should be performed when diagnosis is doubtful, clinical presentation is unusual, or it has prognostic/predictive relevance 1
• Tumor size, depth (relative to superficial fascia), and site must be documented as they carry independent prognostic value 1
• Grading cannot be assigned after preoperative treatment due to therapy-related tissue changes 1

Staging Procedures

Mandatory Imaging for All Sarcomas

• Chest CT scan is mandatory to detect pulmonary metastases, as lungs are the most common metastatic site 1, 2
• MRI of the entire affected bone/extremity with adjacent joints is the best modality for local staging 1
• Plain radiographs in two planes should always be the first investigation for bone sarcomas 1

Additional Staging Based on Histology and Location

Soft Tissue Sarcomas:

• Abdominal/pelvic CT specifically for myxoid liposarcoma due to extrapulmonary metastasis propensity 1, 3
• Spine and pelvic MRI for myxoid liposarcoma (tendency to metastasize to these sites) 3
• Brain CT for alveolar soft part sarcoma, clear cell sarcoma, and angiosarcoma 1
• Regional lymph node assessment (CT/MRI) for epithelioid sarcoma and clear cell sarcoma (higher rates of nodal metastases) 1

Bone Sarcomas:

• Bone scintigraphy to assess distant skeletal disease 1
• Serum alkaline phosphatase (AP) and lactate dehydrogenase (LDH) for osteosarcoma (prognostic value) 1

Optional Advanced Imaging

• Whole-body MRI and PET-CT or PET-MRI are under evaluation for staging and treatment response but are not yet standard 1
• Cost-effectiveness studies are needed before routine incorporation 1

Staging Classification Systems

AJCC/UICC Staging System

The current staging system emphasizes histological grade as the primary determinant, combined with tumor size, depth, and presence of metastases 1

Key Prognostic Factors by Priority:

1. Histological grade (most important) 1
2. Tumor size (equal importance to grade for extremity sarcomas) 4
3. Tumor depth (superficial vs. deep to fascia) 1
4. Presence of metastases (distant or nodal) 1
5. Anatomic site (extremity vs. trunk vs. retroperitoneal) 1

Bone Sarcoma-Specific Adverse Factors

• Detectable primary metastases at presentation 1
• Axial or proximal extremity location 1
• Large tumor size 1
• Elevated serum AP or LDH 1
• Older age 1

Treatment Determination Algorithm

Step 1: Multidisciplinary Team Review

All diagnostic and treatment decisions must be discussed at a specialized sarcoma MDT meeting before any definitive intervention 1, 3

Step 2: Resectability Assessment

• Determined by the surgeon in consultation with the MDT 1
• Based on tumor stage, anatomical location, and patient comorbidities 1

Step 3: Treatment Modality Selection

For Localized Soft Tissue Sarcoma:

• Wide excision with negative margins (R0) is standard, performed by a surgeon specifically trained in sarcoma treatment 1
• Radiation therapy (50-60 Gy) is standard for high-grade, deep tumors >5 cm following wide excision 1, 3
• Preoperative radiotherapy may be considered for radiosensitive subtypes like myxoid liposarcoma 1, 3

For High-Grade Osteosarcoma:

• Curative treatment consists of chemotherapy (doxorubicin, cisplatin, high-dose methotrexate, ifosfamide) plus surgery 1
• Multimodal chemotherapy is preferred, administered before and after surgery 1

For Ewing Sarcoma:

• Complete surgical excision where feasible is preferred over radiation alone 1
• Postoperative radiation for inadequate margins or poor histological response 1

Critical Pitfalls to Avoid

• Never perform inadvertent excision without preoperative diagnosis - this contaminates the surgical field and worsens outcomes 1
• Do not biopsy retroperitoneal or intra-abdominal masses before specialist MDT referral 1
• Avoid laminectomy or decompression for spinal lesions unless absolutely necessary for cord compression 1
• Do not rely on staging systems alone - nomograms provide more personalized risk assessment for adjuvant treatment decisions 1
• Missing extrapulmonary metastases in myxoid liposarcoma by failing to image spine/pelvis is a common error 3
• Underestimation of tumor grade on core biopsy due to heterogeneity and underrepresentation of necrosis requires correlation with imaging 1